Trial Profile

An Open Label, Comparative, Randomized , Phase IV Pilot Study to Evaluate the Efficacy and Safety of a Rilpivarine-based Antiretroviral Tratment Regimen in HIV- Infected Patients With Liver Metabolic Disease Who Maintain Udetectable HIV Viral Load

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 29 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dolutegravir (Primary) ; Dolutegravir/rilpivirine (Primary) ; Emtricitabine/rilpivirine/tenofovir disoproxil fumarate (Primary) ; Rilpivirine (Primary) ; Tenofovir alafenamide (Primary) ; Tenofovir disoproxil fumarate (Primary)
Indications HIV infections
Focus Therapeutic Use
Acronyms MAFALDA-R

18 Jul 2025 Status changed from active, no longer recruiting to completed.
26 Feb 2025 Planned End Date changed from 1 Apr 2025 to 20 Jul 2025.
26 Feb 2025 Planned primary completion date changed from 1 Jan 2025 to 8 Jul 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com